#ChronicLymphocyticLeukemia
LightNews LightNews
andysevenltd.bsky.social
As someone who has CLL this is encouraging news. #leukemia #bloodcancer #cll #chroniclymphocyticleukemia
yocum137.bsky.social Dan Yocum. Ugh. @yocum137.bsky.social · Jun 6
🧪

A friend who had/has lymphocytic leukemia was just treated with this by the VA.

This is freaking amazing science!
erictopol.bsky.social Eric Topol @erictopol.bsky.social · Jun 5
Here again is the remarkable impact of immunotherapy for intractable cancer via engineered T cells
gift link www.nytimes.com/2025/06/03/h...
June 6, 2025 at 5:39 AM
danielbachurski.bsky.social
Would love to be included!I'm working on the immune microenvironment in #chroniclymphocyticleukemia 👋
November 20, 2024 at 4:26 PM
rarediseaseadvisor.bsky.social
In the American Journal of Hematology, Dr Michael Hallek of the @unicologne.bsky.social wrote about the common features of #ChronicLymphocyticLeukemia (CLL), including some of the more notable epidemiological findings in recent years.

Read more: bit.ly/4o3xzjv

#MedSky #RareSky #CLL
Unraveling the Relationship Between CLL and Advanced Age
While advanced age appears to be a risk factor for CLL, the development of CLL also worsens age-related outcomes.
bit.ly
October 22, 2025 at 5:12 PM
dramamath.bsky.social
I have been a cancer survivor for 2,238 days. Thank you ohyouresotough for the art work for National Cancer Survivors Day. #leukemia #chroniclymphocyticleukemia
June 1, 2025 at 11:37 PM
sigtrans-sttt.bsky.social
Researchers reveal #ferroptosis as a targetable vulnerability in #ChronicLymphocyticLeukemia, showing that BTK inhibition increases iron uptake via TFRC, and combining #ibrutinib with #GPX4 or ACSL1 targeting enhances ferroptosis.

#OpenAccess in #STTT: doi.org/10.1038/s413...
January 6, 2026 at 5:01 PM
ashclinicalnews.bsky.social
#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky
December 7, 2025 at 5:30 PM
jeffhinz.bsky.social
It's done, my cancer journey in 4K. If you know anyone with #ChronicLymphocyticLeukemia, please share.

youtu.be/nHnK5bKx90s?...

#CLL #Leukemia #BloodCancer #chatgpt #midjourney #runway #rubbrband #flux #elvenlabs #suno #capcut #cordycepsmilitaris #cordyceps #4k
Cordy Movie
YouTube video by Jeff Hinz
youtu.be
November 25, 2024 at 12:26 PM
rarediseaseadvisor.bsky.social
Patients with chronic lymphocytic leukemia (#CLL) who discontinued covalent #BTKi and later required #BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap.

Read here: https://bit.ly/3YkhbQn

#RareDisease #ChronicLymphocyticLeukemia #MedSky
Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL
Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.
bit.ly
December 15, 2025 at 6:42 PM
jamadermatology.com
Individuals with #ChronicLymphocyticLeukemia faced increased risk of skin cancer-specific metastasis and death compared with controls especially #BasalCellCarcinoma and #SquamousCellCarcinoma, though the absolute risk remained low.

ja.ma/47yZ8ev
Figure 1. Cumulative incidence curve showing 10-year standardized cumulative incidences and absolute risk differences for skin cancer. The graph plots the risk of skin cancer (%) over time since CLL diagnosis (years) for patients with CLL and controls.
April 1, 2026 at 3:30 PM
journal-cer.bsky.social
📢New article alert

New Research Article in JCER compares healthcare resource utilization and costs for first-line treatments for #CLL.

🔗Read here: becarispublishing.com/doi/10.57264...

#ChronicLymphocyticLeukemia #HealthcareCosts #RealWorldData #OpenAccess #JCER
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic...
becarispublishing.com
April 22, 2025 at 4:09 PM
gmj-georgia.bsky.social
Triple therapy breakthrough: Adding pirtobrutinib to venetoclax-rituximab significantly extends progression-free survival in patien…

#BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax

#BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax

h…
Pirtobrutinib boosts CLL survival outcomes
Triple therapy breakthrough: Adding pirtobrutinib to venetoclax-rituximab significantly extends progression-free survival in patien… #BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax
news.gmj.ge
September 15, 2026 at 9:26 AM
gmj-georgia.bsky.social
Triple therapy breakthrough: Adding pirtobrutinib to venetoclax-rituximab significantly extends progression-free survival in patien…

#BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax

#BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax

h…
Pirtobrutinib boosts CLL survival outcomes
Triple therapy breakthrough: Adding pirtobrutinib to venetoclax-rituximab significantly extends progression-free survival in patien… #BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax
news.gmj.ge
September 4, 2026 at 12:41 PM
sigtrans-sttt.bsky.social
What determines #Ferroptosis sensitivity in #ChronicLymphocyticLeukemia? This study identifies #Immunoglobulin heavy-chain status and stromal interactions as key regulators of therapeutic vulnerability.

#CoverPage #OpenAccess: doi.org/10.1038/s413...
Immunoglobulin heavy-chain status and stromal interactions shape ferroptosis sensitivity in chronic lymphocytic leukemia
August 10, 2026 at 3:50 PM
hematologyadvisor.bsky.social
Results from a large observational study from @BrJHaem found patients with CLL with Richter transformation who were treatment exposed demonstrated the shortest TTNTd and OS.📉

This study highlights the need for novel therapies to treat #ChronicLymphocyticLeukemia. Read the data here🔽
bit.ly/4fZXupA
August 7, 2026 at 7:12 PM
rarediseaseadvisor.bsky.social
The Clinical Frailty Scale was associated with early treatment discontinuation among older adults with chronic lymphocytic leukemia (#CLL) treated with #Zanubrutinib. Study in Hematological Oncology.

Read more: https://bit.ly/4aTranu

#RareDisease #ChronicLymphocyticLeukemia #Hematology #Oncology
Frailty Scale May Predict Treatment Cessation in Older Patients With CLL
Among patients with CLL aged 65 years or older receiving zanubrutinib, discontinuation at 12 months was higher in those with CFS above 3.
bit.ly
January 9, 2026 at 10:40 PM
rarediseaseadvisor.bsky.social
Venetoclax–obinutuzumab (#VenObi) demonstrated durable disease control with partial but steady immune restoration through 48 months. @ash.hematology.org

Read more: https://bit.ly/482ZHOf

#RareDisease #ChronicLymphocyticLeukemia #CLL #Hematology
Sustained CLL Clearance With Ven-Obi Supports Durable Immune Recovery
Fixed-duration venetoclax–obinutuzumab sustained chronic lymphocytic leukemia (CLL) cell depletion while permitting measured immune recovery.
bit.ly
November 28, 2025 at 3:05 PM
rarediseaseadvisor.bsky.social
👏 From childhood curiosity to career achievement

Jennifer R. Brown, MD, PhD, Director of the CLL Center at @danafarber.bsky.social has dedicated her life to understanding and advancing treatment for #ChronicLymphocyticLeukemia (CLL). @societyofhemonc.bsky.social

Read more: https://bit.ly/476wgcs
How Childhood Fascination Led to CLL Expertise—and Continued Hope
Jennifer R. Brown, MD, PhD, is SOHO's annual honoree for outstanding achievement.
bit.ly
October 10, 2025 at 4:07 PM
cllsupport.bsky.social
On World Cancer Day, let’s honour those we’ve lost, support those living with cancer, and raise awareness for better prevention and treatment options.

#WorldCancerDay #UnitedByUnique #bloodcancer #ChronicLymphocyticLeukemia
February 4, 2026 at 8:06 AM
ashclinicalnews.bsky.social
In patients with #ChronicLymphocyticLeukemia #CLL, the use of regular prophylactic IgG replacement therapy to help prevent #infection, a common occurrence with the disease, was not associated with a reduced risk of infection-related hospitalizations: https://ow.ly/6L3W50XlOHU
#HemeSky #MedSky
November 3, 2025 at 4:01 PM
ashclinicalnews.bsky.social
Recent research indicates that MRD-guided time-limited treatment with #zanubrutinib, #venetoclax, and #obinutuzumab resulted in deep remissions in patients with previously treated #ChronicLymphocyticLeukemia, with a best uMRD rate of 85%: ow.ly/e16h50WwZ66
#HemeSky
MRD-Guided Treatment Approach Leads to Deep Remissions in CLL | ASH Clinical News | American Society of Hematology
ow.ly
July 31, 2025 at 6:30 PM
jamadermatology.com
Individuals with #ChronicLymphocyticLeukemia faced increased risk of skin cancer-specific metastasis and death compared with controls especially #BasalCellCarcinoma and #SquamousCellCarcinoma, though the absolute risk remained low. ja.ma/4ucGDox
Figure 1: Cumulative incidence curve for skin cancer risk over 10 years. Patients with CLL (blue line) show a significantly higher risk (up to ~13%) compared to Controls (orange line, up to ~7%). ARD is 6.6 pp (95% CI, 5.7-7.4 pp; P<.001). A table below shows numbers at risk for both groups over time.
May 31, 2026 at 2:24 PM
michaelbani.bsky.social
AstraZeneca’s Calquence-venetoclax combo shows incredible results for CLL patients. A hopeful step forward in cancer care. #CancerBreakthrough #LeukemiaTreatmen #Cancer #BloodCancer #Leukemia #CancerTreatment #ChronicLymphocyticLeukemia #MedicalBreakthrough #ScienceNews #HealthUpdates
December 10, 2024 at 12:03 AM